{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-22-000082","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2022-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.965200+00:00","generated_at":"2026-06-25T04:48:43.190851+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Denali Therapeutics elects three Class II directors at 2022 annual meeting","bullets":["Vicki Sato (65.5M for, 15.5M withheld), Erik Harris (80.6M for, 0.3M withheld), and Peter Klein (67.3M for, 13.6M withheld) elected as Class II directors.","Ratification of Ernst & Young as independent auditor for FY2022 passed with 86.8M for, 16K against, 37K abstain.","Non-binding advisory vote on executive compensation approved with 75.8M for, 4.5M against, 0.6M abstain.","70.70% of outstanding shares (86.9M of 122.9M) represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-22-000082","json":"https://secwatch.observer/filing/0001714899-22-000082.json","markdown":"https://secwatch.observer/filing/0001714899-22-000082.md","text":"https://secwatch.observer/filing/0001714899-22-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000082/0001714899-22-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000082/dnli-20220602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T04:48:43.190851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}